Unknown

Dataset Information

0

The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein.


ABSTRACT: Dengue viruses are mosquito-borne flaviviruses that circulate in nature as four distinct serotypes (DENV1-4). These emerging pathogens are responsible for more than 100 million human infections annually. Severe clinical manifestations of disease are predominantly associated with a secondary infection by a heterotypic DENV serotype. The increased risk of severe disease in DENV-sensitized populations significantly complicates vaccine development, as a vaccine must simultaneously confer protection against all four DENV serotypes. Eliciting a protective tetravalent neutralizing antibody response is a major goal of ongoing vaccine development efforts. However, a recent large clinical trial of a candidate live-attenuated DENV vaccine revealed low protective efficacy despite eliciting a neutralizing antibody response, highlighting the need for a better understanding of the humoral immune response against dengue infection. In this study, we sought to identify epitopes recognized by serotype-specific neutralizing antibodies elicited by monovalent DENV1 vaccination. We constructed a panel of over 50 DENV1 structural gene variants containing substitutions at surface-accessible residues of the envelope (E) protein to match the corresponding DENV2 sequence. Amino acids that contribute to recognition by serotype-specific neutralizing antibodies were identified as DENV mutants with reduced sensitivity to neutralization by DENV1 immune sera, but not cross-reactive neutralizing antibodies elicited by DENV2 vaccination. We identified two mutations (E126K and E157K) that contribute significantly to type-specific recognition by polyclonal DENV1 immune sera. Longitudinal and cross-sectional analysis of sera from 24 participants of a phase I clinical study revealed a markedly reduced capacity to neutralize a E126K/E157K DENV1 variant. Sera from 77% of subjects recognized the E126K/E157K DENV1 variant and DENV2 equivalently (<3-fold difference). These data indicate the type-specific component of the DENV1 neutralizing antibody response to vaccination is strikingly focused on just two amino acids of the E protein. This study provides an important step towards deconvoluting the functional complexity of DENV serology following vaccination.

SUBMITTER: VanBlargan LA 

PROVIDER: S-EPMC3857832 | BioStudies | 2013-01-01

REPOSITORIES: biostudies

Similar Datasets

2017-01-01 | S-EPMC6392503 | BioStudies
2020-01-01 | S-EPMC7762770 | BioStudies
2015-01-01 | S-EPMC4620467 | BioStudies
2020-01-01 | S-EPMC7382454 | BioStudies
2019-01-01 | S-EPMC6643441 | BioStudies
2015-01-01 | S-EPMC4689971 | BioStudies
2014-01-01 | S-EPMC3911750 | BioStudies
2018-01-01 | S-EPMC5843351 | BioStudies
1000-01-01 | S-EPMC4730143 | BioStudies
2014-01-01 | S-EPMC4396058 | BioStudies